Neurocrine Biosciences Reports Strong 2025 Sales, Outlines 2026 Priorities

Company touts continued momentum for INGREZZA and successful launch of CRENESSITY, while advancing pipeline of next-gen therapies.

Published on Feb. 11, 2026

Got story updates? Submit your updates here. ›

Neurocrine Biosciences reported total product sales of over $2.8 billion in 2025, up 22% year-over-year, driven by strong performance of its lead drug INGREZZA and a successful launch of CRENESSITY. The company provided guidance for INGREZZA sales in 2026 and outlined plans to expand the commercial team for CRENESSITY to drive further growth. Neurocrine also highlighted progress in its pipeline, including next-generation VMAT2 and CRF programs, as well as late-stage neuropsychiatry studies.

Why it matters

Neurocrine's results demonstrate its ability to maintain momentum with its established products while also successfully launching new therapies. The company's diversified pipeline and strategic R&D focus suggest it is well-positioned to continue delivering value to patients and shareholders in the years ahead.

The details

Neurocrine reported that INGREZZA generated just over $2.5 billion in revenue in 2025, up 9% year-over-year, driven by double-digit volume growth. The company's newer drug CRENESSITY, approved in late 2024, reached over $300 million in net sales during its first full year on the market. Neurocrine plans to expand its CRENESSITY sales force in 2026 to drive further growth, targeting both endocrinologists and primary care providers. The company also highlighted progress in its pipeline, including next-generation VMAT2 and CRF programs, as well as two late-stage neuropsychiatry studies for osavampator in major depressive disorder and direlotide in schizophrenia.

  • Neurocrine's CRENESSITY was approved in December 2024.
  • Neurocrine plans to expand its CRENESSITY sales force in the first quarter of 2026.
  • Top-line data for Neurocrine's phase 3 studies of osavampator and direlotide are expected in 2027.

The players

Neurocrine Biosciences

A biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders.

Kyle Gano

Chief Executive Officer of Neurocrine Biosciences.

Matt Abernethy

Chief Financial Officer of Neurocrine Biosciences.

Eric Benevich

Chief Commercial Officer of Neurocrine Biosciences.

Sanjay Keswani

Chief Medical Officer of Neurocrine Biosciences.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.